M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Research

Executive Summary: M344 is a cell-permeable histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM, enabling potent epigenetic modulation in cellular models (APExBIO). It increases histone acetylation, alters gene expression, and induces cell differentiation. M344 demonstrates nanomolar activity in breast cancer, neuroblastoma, and medulloblastoma cell lines. It enhances responses to radiation and modulates NF-κB and pro-apoptotic pathways. The compound is insoluble in water but highly soluble in DMSO/ethanol, supporting flexible experimental integration (APExBIO).

Biological Rationale

Histone deacetylase inhibitors (HDACi) are foundational in epigenetic research. HDACs regulate chromatin structure by removing acetyl groups from histone tails, leading to condensation and transcriptional repression. Inhibiting HDACs results in hyperacetylated histones, opening chromatin and facilitating gene expression changes. Aberrant HDAC activity is implicated in oncogenesis, cell proliferation, differentiation defects, and disease-related transcriptional silencing (Klotz 2009). M344, developed and supplied by APExBIO, provides a potent, selective approach to modulate HDAC pathways in vitro, supporting both cancer and virology research.

Mechanism of Action of M344

M344 inhibits HDAC enzymes with an IC50 of 100 nM, directly blocking the catalytic site responsible for deacetylation. This inhibition leads to increased levels of acetylated histones (notably H3 and H4), altering chromatin accessibility and gene transcription profiles. M344-induced histone acetylation upregulates pro-apoptotic factors (e.g., Puma) and can activate latent viral promoters such as the HIV-1 LTR, even in the absence of p53 (see mechanistic review). The compound also modulates transcription factor NF-κB, affecting inflammatory and survival signaling pathways. These multimodal effects underpin its efficacy in cancer cell models and in HIV-1 latency reversal assays.

Evidence & Benchmarks

• M344 inhibits HDAC activity with an IC50 of 100 nM in cell-based assays (APExBIO product data).
• In MCF-7 breast cancer cells, M344 suppresses cell proliferation with a GI50 of 0.63 μM (24–72h, DMEM, 37°C) (APExBIO).
• GI50 values for D341 MED (medulloblastoma) and CH-LA 90 (neuroblastoma) cell lines are 0.65 μM (72h, RPMI-1640, 37°C) (APExBIO).
• M344 enhances radiosensitivity in human squamous carcinoma lines SCC-35 and SQ-20B (2 Gy, 24h pretreatment), increasing cell death in clonogenic survival assays (HDAC4.com).
• Promotes expression of pro-apoptotic Puma via p53-independent mechanisms, as shown in apoptosis induction studies (serum-supplemented media, 48h) (GAP-26.com).
• Facilitates HIV-1 latency reversal by activating LTR-driven gene expression in primary CD4+ T cell models (1 μM, 48h, RPMI-1640, 5% CO2) (GAP-26.com).
• Solubility: ≥14.75 mg/mL in DMSO, ≥12.88 mg/mL in ethanol (ultrasonic treatment, 25°C); insoluble in water (APExBIO).
• Recommended experimental concentrations: 1–100 μM, treatment durations 1–7 days (APExBIO).

This article extends the mechanistic depth provided in M344: Potent HDAC Inhibitor with IC50 100 nM for Cancer &... by providing quantitative, condition-specific benchmarks and explicit workflow integration guidance for cancer and HIV-1 research. For practical assay design guidance, see also M344 (SKU A4105): Reliable HDAC Inhibition for Cell-Based..., which this article augments with updated solubility and storage parameters.

Applications, Limits & Misconceptions

Applications:

• Epigenetic modulation for cancer cell differentiation and apoptosis assays.
• Cell proliferation inhibition in breast cancer, medulloblastoma, and neuroblastoma models.
• Enhancement of radiotherapy efficacy in squamous carcinoma models.
• HIV-1 latency reversal in primary CD4+ T cells via LTR activation.
• Transcription factor (NF-κB) signaling studies.

Common Pitfalls or Misconceptions

• M344 is not soluble in water; use only DMSO or ethanol as solvents with ultrasonic treatment for optimal dissolution (APExBIO).
• It is not intended for in vivo or clinical use; research use only.
• Long-term storage of M344 in solution is not recommended; store as a solid at -20°C (APExBIO).
• Exceeding recommended concentrations (>100 μM) may induce off-target cytotoxicity.
• M344’s effects are not p53-dependent; apoptosis induction can occur via alternative pathways.

For a translational perspective on tumor microenvironment modulation, see M344: Next-Generation HDAC Inhibitor for Tumor Microenvir.... This article clarifies the compound’s specific solubility and storage limitations not detailed previously.

Workflow Integration & Parameters

• Solvent: Dissolve M344 in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL) using ultrasonic bath at 25°C; avoid water.
• Stock Storage: Store solid at -20°C, desiccated; avoid long-term storage in solution.
• Concentration Range: 1–100 μM for most cell-based assays; optimize per cell line.
• Treatment Duration: 1–7 days; monitor for cytotoxicity and differentiation endpoints.
• Shipping: Shipped on blue ice; allow for gradual equilibration to room temperature before use.
• Controls: Include DMSO or ethanol-only vehicle controls for all experiments.

For detailed assay troubleshooting and reproducibility tips, refer to M344 (SKU A4105): Reliable HDAC Inhibition for Cell-Based.... This article updates with concentration and solvent handling specifics for maximal reproducibility.

Conclusion & Outlook

M344 provides a robust, well-characterized tool for HDAC pathway interrogation in cancer and HIV-1 latency research. Its nanomolar potency, clear solubility guidelines, and versatility in multiple cell models support high reproducibility and translational relevance. Future perspectives include combinatorial studies with radiotherapy and further exploration in epigenetic reprogramming. For specifications and ordering, visit the M344 product page at APExBIO.